Palliative care cancer patients starting with opioids MedDRA version: 9.1 Level: LLT Classification code 10010774 Term: Constipation
Conditions
Interventions
Trade Name: Movicolon
Product Name: .
Pharmaceutical Form: Powder for oral suspension
INN or Proposed INN: Kaliumchloride
CAS Number: 7447-40-7
Concentration unit: mg milligram(s)
Concentration type:
Sponsors
UMC Utrecht
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Palliative care cancer patients started on morphine, fentanyl, oxycocodon, hydromorphon, methadone, codeine or tramadol Age >18 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patients with a contra-indication for laxatives Patiens who have used laxatives within four weeks prior to inclusion in the study Estimated life expectancy <3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare magnesiumoxide and Movicolon with regard to the prevention of constipation in palliative care cancer patients started on opioids;Secondary Objective: To compare magnesiumoxide and Movicolon with regard to side effects and patient preference in palliative care cancer patients started on opioids;Primary end point(s): Level of constipation (as assessed by the PAC SYM, a constipation symptom assessment instrument) | — |
Countries
Netherlands
Outcome results
None listed